Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test.
A single blood test can now detect multiple cancers and organ problems simultaneously, potentially catching some early-stage disease before symptoms appear.
Researchers developed MethylScan, a cost-effective cfDNA methylome sequencing platform that simultaneously detects multiple cancers and organ abnormalities using a single blood test. In 1,061 individuals, it achieved strong diagnostic performance for multicancer detection including early-stage cancers, liver cancer surveillance, and disease classification.
What the study was
- Study design
- Diagnostic validation cohort study
- Population
- General population and high-risk liver disease patients
- Sample size
- 1061
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Proceedings of the National Academy of Sciences of the United States of America
Why it surfaced
Novel cost-effective cfDNA methylome platform validated in 1,061 individuals with strong multicancer detection performance in PNAS. Addresses key cost barrier to cfDNA-based screening.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.